Idiopathic Thrombocytopenic Purpura
- Author: Michael A Silverman, MD, MD; Chief Editor: Gil Z Shlamovitz, MD, FACEP more...
Idiopathic thrombocytopenic purpura (ITP), also known as primary immune thrombocytopenic purpura and autoimmune thrombocytopenic purpura, is defined as isolated thrombocytopenia with normal bone marrow and in the absence of other causes of thrombocytopenia. ITP has two distinct clinical syndromes, manifesting as an acute condition in children and a chronic condition in adults.
ITP is primarily a disease of increased peripheral platelet destruction, with most patients having antibodies to specific platelet membrane glycoproteins. Relative marrow failure may contribute to this condition, since studies show that most patients have either normal or diminished platelet production.
Acute ITP often follows an acute infection and has a spontaneous resolution within 2 months. Chronic ITP persists longer than 6 months without a specific cause.
Incidence rates are as follows:
The incidence of ITP in adults is approximately 66 cases per 1,000,000 per year
An average estimate of the incidence in children is 50 cases per 1,000,000 per year
New cases of chronic refractory ITP comprise approximately 10 cases per 1,000,000 per year
According to studies in Denmark and England, childhood ITP occurs in approximately 10-40 cases per 1,000,000 per year. A prospective, population-based study in Norway indicated an incidence of 53 per 1,000,000 in children younger than 15 years. A study in Kuwait reported a higher incidence of 125 cases per 1,000,000 per year.
Hemorrhage represents the most serious complication; intracranial hemorrhage is the most significant. The mortality rate from hemorrhage is approximately 1% in children and 5% in adults. In patients with severe thrombocytopenia, predicted 5-year mortality rates from bleeding are significantly raised in patients older than 60 years versus patients younger than 40 years, 47.8% versus 2.2%, respectively. Older age and previous history of hemorrhage increase the risk of severe bleeding in adult ITP.
Spontaneous remission occurs in more than 80% of cases in children. However, it is uncommon in adults.
See the list below:
Peak prevalence occurs in adults aged 20-50 years.
Peak prevalence occurs in children aged 2-4 years.
Approximately 40% of all patients are younger than 10 years.
Sex- and Age-related Demographics
In chronic ITP (adults), the female-to-male ratio is 2.6:1. More than 72% of patients older than 10 years are female. In acute ITP (children), distribution is equal between males (52%) and females (48%).
In adults, the peak prevalence is from 20-50 years of age. In children, peak prevalence is from 2-4 years of age. Approximately 40% of all patients are younger than 10 years.
Reese JA, Li X, Hauben M, Aster RH, Bougie DW, Curtis BR, et al. Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood. 2010 Sep 23. 116(12):2127-33. [Medline]. [Full Text].
Warkentin TE, Anderson JA. DITP causation: 3 methods better than 1?. Blood. 2010 Sep 23. 116(12):2002-3. [Medline].
[Guideline] Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011 Apr 21. 117(16):4190-207. [Medline]. [Full Text].
Schultz CL, Mitra N, Schapira MM, Lambert MP. Influence of the American Society of Hematology guidelines on the management of newly diagnosed childhood immune thrombocytopenia. JAMA Pediatr. 2014 Oct. 168(10):e142214. [Medline].
Williams JA, Boxer LA. Combination therapy for refractory idiopathic thrombocytopenic purpura in adolescents. J Pediatr Hematol Oncol. 2003 Mar. 25(3):232-5. [Medline].
Pasa S, Altintas A, Cil T, Danis R, Ayyildiz O. The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura. J Thromb Thrombolysis. 2008 Mar 3. [Medline].
Khellaf M, Charles-Nelson A, Fain O, Terriou L, Viallard JF, Cheze S, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 2014 Nov 20. 124(22):3228-36. [Medline].
Rodeghiero F, Ruggeri M. Chronic immune thrombocytopenic purpura. New agents. Hamostaseologie. 2009 Jan. 29(1):76-9. [Medline].
Cersosimo RJ. Romiplostim in chronic immune thrombocytopenic purpura. Clin Ther. 2009 Sep. 31(9):1887-907. [Medline].
Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008 Feb 2. 371(9610):395-403. [Medline].
Blanchette VS, Luke B, Andrew M, et al. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr. 1993 Dec. 123(6):989-95. [Medline].
Borst F, Keuning JJ, van Hulsteijn H, Sinnige H, Vreugdenhil G. High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults. Ann Hematol. 2004 Dec. 83(12):764-8. [Medline].
Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002 Mar 28. 346(13):995-1008. [Medline].
El Alfy MS, Mokhtar GM, El-Laboudy MA, Khalifa AS. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura. Acta Haematol. 2006. 115(1-2):46-52. [Medline].
Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood. 1999 Aug 1. 94(3):909-13. [Medline].
George JN, el-Harake MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. N Engl J Med. 1994 Nov 3. 331(18):1207-11. [Medline].
Heegaard ED, Rosthoj S, Petersen BL, et al. Role of parvovirus B19 infection in childhood idiopathic thrombocytopenic purpura. Acta Paediatr. 1999 Jun. 88(6):614-7. [Medline].
Longhurst HJ, O'Grady C, Evans G, et al. Anti-D immunoglobulin treatment for thrombocytopenia associated with primary antibody deficiency. J Clin Pathol. 2002 Jan. 55(1):64-6. [Medline].
Maloisel F, Andres E, Zimmer J. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med. 2004 May 1. 116(9):590-4. [Medline].
McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood. 2004 Aug 15. 104(4):956-60. [Medline].
Newman GC, Novoa MV, Fodero EM. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol. 2001 Mar. 112(4):1076-8. [Medline].
Ojima H, Kato T, Araki K. Factors predicting long-term responses to splenectomy in patients with idiopathic thrombocytopenic purpura. World J Surg. 2006 Apr. 30(4):553-9. [Medline].
Rodeghiero F. First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat. Eur J Haematol Suppl. 2008 Feb. 19-26. [Medline].
Sandler SG. Intravenous Rh immune globulin for treating immune thrombocytopenic purpura. Curr Opin Hematol. 2001 Nov. 8(6):417-20. [Medline].
Sukenik-Halevy R, Ellis MH, Fejgin MD. Management of immune thrombocytopenic purpura in pregnancy. Obstet Gynecol Surv. 2008 Mar. 63(3):182-8. [Medline].
Thude H, Gruhn B, Werner U. Treatment of a patient with chronic immune thrombocytopenic purpura with rituximab and monitoring by flow cytometric analysis. Acta Haematol. 2004. 111(4):221-4. [Medline].
Vranou M, Platokouki H, Pergantou H, Aronis S. Recurrent idiopathic thrombocytopenic purpura in childhood. Pediatr Blood Cancer. 2008 Apr 17. [Medline].
Watts RG. Idiopathic thrombocytopenic purpura: a 10-year natural history study at the childrens hospital of alabama. Clin Pediatr (Phila). 2004 Oct. 43(8):691-702. [Medline].
Zeller B, Helgestad J, Hellebostad M. Immune thrombocytopenic purpura in childhood in Norway: a prospective, population-based registration. Pediatr Hematol Oncol. 2000 Oct-Nov. 17(7):551-8. [Medline].
Provan D, Newland AC. Current Management of Primary Immune Thrombocytopenia. Adv Ther. 2015 Oct. 32 (10):875-87. [Medline]. [Full Text].
Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010 Jan 14. 115 (2):168-86. [Medline]. [Full Text].